ANTX - CONSENSUS CO - AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. (ANTX) focuses on developing anti-infective agents while outsourcing production and testing to third-party contractors to minimize capital expenditures. The business possesses strong defensive qualities, as demand for lung therapy remains independent of market cycles. This chart on the GURU.Markets platform shows a consensus forecast of 8.99. However, the company's survival currently depends on the resumption of clinical trials amid extremely low cash reserves.

For AN2 Therapeutics, Inc. (ANTX), the consensus target price aggregates average fair value estimates from leading analysts, establishing a dynamic benchmark for the asset's fundamental attractiveness. This indicator reflects overall market confidence in the company's capitalization, which is currently being adjusted to account for risks of international clinical trial disruptions and logistical gaps in biomaterial supplies caused by geopolitical instability.